检索结果-南通市图书馆

Does Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer?

World Journal of Gastroenterology 2009年第34期15卷 4290-4297页

作者： Katsuhiro Mabe Mikako Takahashi Haruhumi Oizumi hideaki tsukuma Akiko Shibata Kazutoshi Fukase Toru Matsuda Hiroaki Takeda Sumio Kawata Division of Gastroenterology KKR Sapporo Medical Center Internal Medicine Tsuruoka Kyoritsu Hospital Internal Medicine Oizumi Medical Clinic Department of Cancer Control and Statistics Osaka Medical Center for Cancer and Cardiovascular Diseases Yamagata Prefectural Medical Center for Cancer and Lifestyle-Related Disease Internal Medicine Yamagata Prefectural Central Hospital Yamagata Prefectural Shonai Public Health Center Department of Gastroenterology Faculty of MedicineYamagata University

AIM:To investigate the effects of Helicobacter pylori (H pylori)eradication therapy for treatment of peptic ulcer on the incidence of gastric cancer. METHODS:A multicenter prospective cohort study was conducted between November 2000 and December 2007 in Yamagata Prefecture,*** study included patients with H pylori-positive peptic ulcer who decided themselves whether to receive H pylori eradication(eradication group)or conventional antacid therapy(non-eradication group).Incidence of gastric cancer in the two groups was determined based on the results of annual endoscopy and questionnaire surveys,as well as Yamagata Prefectural Cancer Registry data,and was compared between the two groups and by results of H pylori ***:A total of 4133 patients aged between 13 and 91 years(mean 52.9 years)were registered,and 56 cases of gastric cancer were identified over a mean follow-up of 5.6 *** sex-and age-adjusted incidence ratio of gastric cancer in the eradication group, as compared with the non-eradication group,was 0.58 (95%CI:0.28-1.19)and ratios by follow-up period(3 years)were 1.16(0.27-5.00),0.50 (0.17-1.49),and 0.34(0.09-1.28),*** follow-up tended to be associated with better prevention of gastric cancer,although not to a significant *** significant difference in incidence of gastric cancer was observed between patients with successful eradication therapy(32/2451 patients,1.31%)and those with treatment failure(11/639 patients,1.72%).Among patients with duodenal ulcer,which is known to be more prevalent in younger individuals,the incidence of gastric cancer was significantly less in those with successful eradication therapy(2/845 patients,0.24%)than in those with treatment failure(3/216 patients,1.39%). CONCLUSION:H pylori eradication therapy for peptic ulcer patients with a mean age of 52.9 years at registration did not significantly decrease the incidence of gastric cancer.

关键词： Helicobacter pylori Peptic ulcer Gastric cancer Eradication therapy Cancer prevention

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Phase Ⅱ study of protracted irinotecan infusion and a low-dose cisplatin for metastatic gastric cancer

引用

World Journal of Gastroenterology 2006年第40期12卷 6522-6526页

作者： Hiroshi Imamura Masataka Ikeda Hiroshi Furukawa Toshimasa Tsujinaka Kazumasa Fujitani Kenji Kobayashi Hiroyuki Narahara Michio Kato Haruhiko Imamoto Arimichi Takabayashi hideaki tsukuma Department of Surgery Sakai Municipal Hospital Osaka Japan Department of Surgery Osaka National Hospital Osaka Japan Department of Surgery Kinki Central Hospital Hyogo Japan Department of Internal Medicine Osaka Medical Center for Cancer and Cardiovascular Diseases Osaka Japan Department of Surgery Kinki University School of Medicine Osaka Japan Department of Surgery Kansai Rosai Hospital Hyogo Japan Department of Surgery Kitano Hospital & Research Institute Osaka Japan

AIM: To test protracted irinotecan infusion plus a low-dose cisplatin in this Phase Ⅱ trial to decrease its toxic-ity. METHODS: The eligibility criteria were: (1) histologi-cally proven measurable gastric cancer; (2) performance status of 0 or 1; (3) no prior chemotherapy or comple-tion of prior therapy at least 4 wk before enrollment; (4) adequate function of major organs; (5) no other active malignancy; and (6) written informed consent. The regi-men consisted of irinotecan (60 mg/m2) on d 1 and 15 by 24-h infusion and cisplatin (10 mg/m2) on d 1, 2, 3, 15, 16, and 17. Treatment was repeated every 4 wk. RESULTS: Thirty-one patients were registered between April 2000 and January 2001. The response rate for all 31 patients, 20 patients without prior chemotherapy, and 11 patients with prior chemotherapy was 52% (16/31), 60% (12/20), and 36% (4/11), respectively. The median survival time was 378 d. The median number of courses given to all patients was 2. Grade 4 neutropenia oc-curred in 11 (35%) patients, while grade 3 to 4 diarrhea or nausea occurred in 1 (3%) and 3 (10%) patients, respectively. Fatigue was minimal as grade 1 fatigue was found only in 3 (10%) patients. Other adverse events were mild and no treatment-related deaths ***: This regimen showed a high level of ac-tivity and acceptable toxicity in patients with metastatic gastric cancer.

关键词： Gastric cancer CPT-11 CDDP Protracted Irinotecan Chemotherapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

主胰管轻度扩张和胰腺囊肿作为胰腺癌发生的提示征象——前瞻性研究

引用

国际医学放射学杂志 2010年第3期 277-277页

作者：汪禾青 S. Tanaka M. Nakao T. Ioka R.Takakura Y. Takano H. tsukuma Department of Cancer Survey Osaka Medical Center for Cancer& CVD

摘要目的前瞻性研究超声显示的主胰管轻度扩张和胰腺囊肿是否为胰腺癌的提示征象。材料与方法本研究经伦理委员会批准,

关键词：胰腺癌主胰管魏氏管胰腺囊肿征象前瞻性研究

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：